Boston Scientific Corp financial data

Symbol
BSX on NYSE
Industry
Surgical & Medical Instruments & Apparatus
Location
300 Boston Scientific Way, Marlborough, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 151 % +7.35%
Quick Ratio 50.3 % +1.11%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.47B shares +0.57%
Entity Public Float 79B USD
Common Stock, Value, Issued 17M USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.47B shares +1.69%
Weighted Average Number of Shares Outstanding, Diluted 1.48B shares +1.92%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 15.2B USD +13.6%
Operating Income (Loss) 2.47B USD +35.4%
Nonoperating Income (Expense) -329M USD -4.11%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 2.14B USD +41.9%
Income Tax Expense (Benefit) 319M USD -46.8%
Earnings Per Share, Basic 1.25 USD/shares +108%
Earnings Per Share, Diluted 1.23 USD/shares +105%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.91B USD +584%
Inventory, Net 2.61B USD +15.9%
Other Assets, Current 756M USD -2.2%
Assets, Current 8.99B USD +52.8%
Deferred Income Tax Assets, Net 3.8B USD -1.66%
Property, Plant and Equipment, Net 2.95B USD +16.5%
Operating Lease, Right-of-Use Asset 416M USD -6.52%
Intangible Assets, Net (Excluding Goodwill) 5.42B USD -10.7%
Goodwill 14.4B USD +5.4%
Other Assets, Noncurrent 1.55B USD -2.76%
Assets 37.1B USD +10.4%
Accounts Payable, Current 906M USD +0.78%
Employee-related Liabilities, Current 948M USD +12.5%
Accrued Liabilities, Current 2.32B USD +7.21%
Liabilities, Current 5.58B USD +22.2%
Long-term Debt and Lease Obligation 8.99B USD +5.85%
Accrued Income Taxes, Noncurrent 356M USD -27.2%
Deferred Income Tax Liabilities, Net 132M USD -2.22%
Operating Lease, Liability, Noncurrent 365M USD -8.98%
Other Liabilities, Noncurrent 1.8B USD -6.54%
Accumulated Other Comprehensive Income (Loss), Net of Tax 164M USD -21.2%
Retained Earnings (Accumulated Deficit) 1.64B USD
Stockholders' Equity Attributable to Parent 20.4B USD +11.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 20.6B USD +11.5%
Liabilities and Equity 37.1B USD +10.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 164M USD -13.7%
Net Cash Provided by (Used in) Financing Activities 1.57B USD
Net Cash Provided by (Used in) Investing Activities -285M USD +41.1%
Common Stock, Shares Authorized 2B shares 0%
Common Stock, Shares, Issued 1.73B shares +0.49%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.44B USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.06B USD +394%
Deferred Tax Assets, Valuation Allowance 1.22B USD +21.5%
Deferred Tax Assets, Gross 3.71B USD -2.42%
Operating Lease, Liability 466M USD +14.2%
Depreciation 385M USD +11%
Payments to Acquire Property, Plant, and Equipment 179M USD +61.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.78B USD +160%
Lessee, Operating Lease, Liability, to be Paid 539M USD +9.55%
Property, Plant and Equipment, Gross 6.51B USD +9.23%
Operating Lease, Liability, Current 76M USD +24.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +30.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 74M USD -11.9%
Deferred Tax Assets, Operating Loss Carryforwards 744M USD +45.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 478M USD +1.49%
Amortization of Intangible Assets 842M USD +3.44%
Depreciation, Depletion and Amortization 304M USD +6.67%
Deferred Tax Assets, Net of Valuation Allowance 3.81B USD -3.57%
Interest Expense 276M USD +5.34%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%